35-PUB: Glycemic Control and Quality of Life in Patients with Type 1 Diabetes from Brazil Treated with Automated Insulin Delivery Systems

Automated insulin delivery systems (AID) such as AAPS or Medtronic's 780G™ pump may reduce the burden of decision-making for patients with type 1 diabetes (T1D). This study aims to compare quality of life (QOL) and glycemic control between patients with T1D that receive AID systems and other treatments in the Brazilian population.This was a study that included T1D patients reached through an online survey via social media. Remote data was collected with an AirTable form, including questions about education, glucose control and QOL questionnaire (DQOL-Brazil).The study groups comprised 228 patients with a mean age and disease duration of 30.4 ± 11.4 and 13.5 ± 10.7 years, respectively. They were divided in groups: 78 with automation (Group A) and 150 without automation (Group B). Group A had a higher proportion of patients or caregivers with higher education (p 0.01; 74.7 vs 48% and 88.9 vs 51.5%, respectively), lower A1c (6.6± 0.8% vs 7.5± 2.3%; p0.001), more A1c 7% (65.8 vs 56.1%; p 0.001), lower severe hypoglycemic events in a year (0.5 ± 1.1 vs 1.8 ± 1.9; p 0.001) and better DQOL scores (93.1 ± 27.4 vs 120.8 ± 28.7; p 0.001) than group B. Weekly mean reported hypoglycemia rates were similar between groups (3.51 ± 2.09 in A vs 3.4 ± 1.9 in B; p=0.73). More patients in group A reported being moderately of very satisfied with time spent to manage diabetes (52.6 vs 12.7%; p0.001) and being moderately/very happy with current treatment (67.9 vs 18%; p 0.001) than in group B. Similar results were seen when only patients using sensors were included, except for the difference in A1c (6.6 ± 0,8% vs 7.1 ± 1.7%; p=0.12) and % A1c 7% (66.7 vs 54.3; p=0.13), which did not persist.In this sample, patients with T1D and AID had better QOL and glycemic control, with a lower rate of severe hypoglycemia than others. Although A1c did not differ between patients who did not use AID systems but had sensors and those in AID systems, differences in QOL and hypoglycemia rates were still seen. Disclosure L. Messias: None. G.L. Ventura: None. M.P. Dantas: None. J.R. Dantas: None. D.L. Souto: None. M. Machado: None. T. Oliveira: None. E.P. Santos: None. T.M. Soares: None. L. Zajdenverg: None. M. Rodacki: None.